This drug combines 3 targets per phase 2 docs [1]. Weight loss and side-effects both show dose-response relations. Side-effects could be higher than single-target drugs d/t more off-target effects, or they could be lower if per-target dosage can be lower d/t reaching therapeutic effect via combination.

Phase 3 "TRIUMPH" study results not due until 2026. Indications only target overweight patients with osteoarthritis, type-II diabetes or cardiovascular disease. [2] There are also reports that it reduces fat in the liver, so it could be useful for fatty liver disease.

No trial I found is studying discontinuation or dependence.

[1] phase 2: https://pubmed.ncbi.nlm.nih.gov/37366315/

[2] phase 3 (TRIUMPH): https://investor.lilly.com/news-releases/news-release-detail...